AU2018290287B2 - Gastro-resistant controlled release oral dosage forms - Google Patents

Gastro-resistant controlled release oral dosage forms Download PDF

Info

Publication number
AU2018290287B2
AU2018290287B2 AU2018290287A AU2018290287A AU2018290287B2 AU 2018290287 B2 AU2018290287 B2 AU 2018290287B2 AU 2018290287 A AU2018290287 A AU 2018290287A AU 2018290287 A AU2018290287 A AU 2018290287A AU 2018290287 B2 AU2018290287 B2 AU 2018290287B2
Authority
AU
Australia
Prior art keywords
bfb
hypromellose
hours
dosage form
gastro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018290287A
Other languages
English (en)
Other versions
AU2018290287A1 (en
Inventor
Emmanuelle GEORGI
Remy LUTHRINGER
Nadine Noel
Jay SAOUD
Sandra Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Neurosciences Inc
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018290287(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of AU2018290287A1 publication Critical patent/AU2018290287A1/en
Application granted granted Critical
Publication of AU2018290287B2 publication Critical patent/AU2018290287B2/en
Priority to AU2024219717A priority Critical patent/AU2024219717A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018290287A 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms Active AU2018290287B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024219717A AU2024219717A1 (en) 2017-06-21 2024-09-13 Gastro-resistant controlled release oral dosage forms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
US62/523,204 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219717A Division AU2024219717A1 (en) 2017-06-21 2024-09-13 Gastro-resistant controlled release oral dosage forms

Publications (2)

Publication Number Publication Date
AU2018290287A1 AU2018290287A1 (en) 2020-01-16
AU2018290287B2 true AU2018290287B2 (en) 2024-06-13

Family

ID=62904624

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018290287A Active AU2018290287B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms
AU2024219717A Pending AU2024219717A1 (en) 2017-06-21 2024-09-13 Gastro-resistant controlled release oral dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219717A Pending AU2024219717A1 (en) 2017-06-21 2024-09-13 Gastro-resistant controlled release oral dosage forms

Country Status (15)

Country Link
US (3) US11464744B2 (OSRAM)
EP (1) EP3641732A1 (OSRAM)
JP (3) JP2020525436A (OSRAM)
CN (1) CN111511353A (OSRAM)
AU (2) AU2018290287B2 (OSRAM)
BR (1) BR112019027398A2 (OSRAM)
CA (1) CA3067031A1 (OSRAM)
CL (1) CL2019003743A1 (OSRAM)
CO (1) CO2019014496A2 (OSRAM)
IL (3) IL319156A (OSRAM)
MX (1) MX2023002994A (OSRAM)
PE (1) PE20200732A1 (OSRAM)
UA (1) UA127349C2 (OSRAM)
WO (1) WO2018237207A1 (OSRAM)
ZA (1) ZA202409847B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501217A (ja) 2014-12-02 2018-01-18 田辺三菱製薬株式会社 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
GB2591667A (en) 2018-08-21 2021-08-04 Minerva Neurosciences Inc Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102482T1 (de) 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
KR100259107B1 (ko) 1992-04-23 2000-07-01 슈테펜 엘. 네스비트 세로토닌 5ht₂길항제로서의 4-이미도메틸-1-[2'-페닐-2'-옥소에틸]피페리딘, 이의 제조방법 및 이를 포함하는 약제학적 조성물
EP1260512B1 (en) 2000-02-29 2007-07-04 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
DK1345595T3 (da) 2000-09-29 2007-09-10 Solvay Pharm Bv Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP5281395B2 (ja) 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のｇｌｙｔ１阻害剤としてのシクロヘキサンスルホニル誘導体
JP2009525979A (ja) 2006-02-07 2009-07-16 田辺三菱製薬株式会社 ４−アシルアミノピリジン誘導体を介した神経新生
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JP2008273954A (ja) 2007-03-30 2008-11-13 Mitsubishi Tanabe Pharma Corp うつ病の予防及び／又は治療剤
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
WO2010133609A2 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
PL2595485T3 (pl) 2010-07-20 2022-06-20 Minerva Neurosciences, Inc. Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigma
DK3135286T3 (da) 2010-07-20 2023-11-27 Minerva Neurosciences Inc Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af skizofreni og symptomer derpå
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2013023250A1 (en) * 2011-08-16 2013-02-21 Baker Idi Heart & Diabetes Institute Holdings Limited Controlled-release formulation
CA2904389C (en) * 2013-03-14 2018-09-18 Jerome J. Schentag Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
JP6531093B2 (ja) 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US9956292B2 (en) * 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
JP2018501217A (ja) 2014-12-02 2018-01-18 田辺三菱製薬株式会社 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
WO2017205393A1 (en) 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. Compositions and methods for treating negative symptoms in non-schizophrenic patients
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
GB2591667A (en) 2018-08-21 2021-08-04 Minerva Neurosciences Inc Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Also Published As

Publication number Publication date
EP3641732A1 (en) 2020-04-29
PE20200732A1 (es) 2020-07-23
IL271606A (en) 2020-02-27
JP2023175778A (ja) 2023-12-12
US20220401368A1 (en) 2022-12-22
IL308650A (en) 2024-01-01
IL271606B1 (en) 2024-01-01
RU2020102015A3 (OSRAM) 2021-10-04
CN111511353A (zh) 2020-08-07
JP2025134828A (ja) 2025-09-17
ZA202409847B (en) 2025-09-25
AU2018290287A1 (en) 2020-01-16
US20250009665A1 (en) 2025-01-09
AU2024219717A1 (en) 2024-10-03
IL308650B1 (en) 2025-04-01
US11464744B2 (en) 2022-10-11
RU2020102015A (ru) 2021-07-21
JP2020525436A (ja) 2020-08-27
BR112019027398A2 (pt) 2020-07-07
CL2019003743A1 (es) 2020-07-03
US20190038561A1 (en) 2019-02-07
US12048768B2 (en) 2024-07-30
CA3067031A1 (en) 2018-12-27
IL319156A (en) 2025-04-01
MX2023002994A (es) 2023-09-15
WO2018237207A1 (en) 2018-12-27
CO2019014496A2 (es) 2020-04-01
IL308650B2 (en) 2025-08-01
IL271606B2 (en) 2024-05-01
UA127349C2 (uk) 2023-07-26

Similar Documents

Publication Publication Date Title
AU2018290287B2 (en) Gastro-resistant controlled release oral dosage forms
AU2023258386B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
JP2009515952A (ja) 制御放出性製剤のクエチアピン
RU2812901C2 (ru) Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением
US20070053975A1 (en) Ramipril formulation
TWI841545B (zh) 耐胃性控制釋放經口劑型
TW202228698A (zh) 用於治療亨丁頓舞蹈症的片劑及其製備方法
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
CN111096952A (zh) 氨磺必利口腔崩解片及其制备方法
EP4565232A1 (en) A stable tablet-in-tablet composition for nausea vomiting in pregnancy
TW202329971A (zh) 抗纖維化組合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)